Patents by Inventor Steven M. Ruben

Steven M. Ruben has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Human tumor necrosis factor TR21 and methods based thereon
    Patent number: 7112410
    Abstract: The present invention relates to TR21 polypeptides. In particular, isolated nucleic acid molecules are provided encoding human TR21 protein. TR21 polypeptides are also provided as are vectors, host cells and recombinant methods for producing the same. The invention further relates to screening methods for identifying agonists and antagonists of TR21 activity. The invention further relates to the treatment, diagnosis, or prognosis of autoimmune diseases or disorders including Sjogren's syndrome using TR21 polynucleotides, polypeptides, agonists or antagonists.
    Type: Grant
    Filed: August 28, 2002
    Date of Patent: September 26, 2006
    Assignee: Human Genome Sciences, Inc.
    Inventors: Steven M. Ruben, David Hilbert
  • Antibodies to human oncogene induced secreted protein I
    Patent number: 7109306
    Abstract: The present invention relates to a novel protein, the Human Oncogene Induced Secreted Protein I (“HOIPS I”) protein. In particular, isolated nucleic acid molecules are provided encoding the human HOIPS I protein. HOIPS I polypeptides are also provided as are vectors, host cells and recombinant methods for producing the same. Antibodies to human HOIPS I are also provided, as are diagnostic methods for detecting abnormal cell proliferation and differentiation disorders and therapeutic methods for treating the same.
    Type: Grant
    Filed: August 3, 2004
    Date of Patent: September 19, 2006
    Assignee: Human Genome Sciences, Inc.
    Inventors: Henrik S. Olsen, Steven M. Ruben
  • Secreted protein HHTLF25 antibodies
    Patent number: 7105644
    Abstract: The present invention relates to novel human secreted proteins and isolated nucleic acids containing the coding regions genes encoding such proteins. Also provided are vectors, host cells, antibodies, and recombinant methods for producing human secreted proteins. The invention further relates to diagnostic and therapeutic methods useful for diagnosing and treating disorders related to these novel human secreted proteins. Disclosed embodiments of the invention also include antibodies that bind to secreted protein HHTLF25 and methods for making and using such antibodies.
    Type: Grant
    Filed: October 25, 2001
    Date of Patent: September 12, 2006
    Assignee: Human Genome Sciences, Inc.
    Inventors: Craig A. Rosen, Steven M. Ruben, David W. LaFleur
  • Protein HDPBQ71
    Patent number: 7091315
    Abstract: The present invention relates to novel human secreted proteins and isolated nucleic acids containing the coding regions of the genes encoding such proteins. Also provided are vectors, host cells, antibodies, and recombinant methods for producing human secreted proteins. The invention further relates to diagnostic and therapeutic methods useful for diagnosing and treating diseases, disorders, and/or conditions related to these novel human secreted proteins.
    Type: Grant
    Filed: March 22, 2002
    Date of Patent: August 15, 2006
    Assignee: Human Genome Sciences, Inc.
    Inventors: Steven M. Ruben, Craig A. Rosen, Henrik Olsen
  • Apoptosis related polynucleotides, polypeptides, and antibodies
    Patent number: 7078186
    Abstract: The present invention relates to novel human apoptosis related polypeptides and isolated nucleic acids containing the coding regions of the genes encoding such polypeptides. Also provided are vectors, host cells, antibodies, and recombinant methods for producing human apoptosis related polypeptides. The invention further relates to diagnostic and therapeutic methods useful for diagnosing and treating disorders related to these novel human apoptosis related polypeptides.
    Type: Grant
    Filed: December 13, 2001
    Date of Patent: July 18, 2006
    Assignee: Human Genome Sciences, Inc.
    Inventors: Jian Ni, Paul E. Young, Steven M. Ruben
  • Antibodies that immunospecifically bind to trail receptors
    Patent number: 7064189
    Abstract: The present invention relates to antibodies and related molecules that immunospecifically bind to TRAIL receptor, TR4. Such antibodies have uses, for example, in the prevention and treatment of cancers and other proliferative disorders. The invention also relates to nucleic acid molecules encoding anti-TR4 antibodies, vectors and host cells containing these nucleic acids, and methods for producing the same. The present invention relates to methods and compositions for preventing, detecting, diagnosing, treating or ameliorating a disease or disorder, especially cancer and other hyperproliferative disorders, comprising administering to an animal, preferably a human, an effective amount of one or more antibodies or fragments or variants thereof, or related molecules, that immunospecifically bind to TRAIL receptor TR4.
    Type: Grant
    Filed: May 7, 2002
    Date of Patent: June 20, 2006
    Assignee: Human Genome Sciences, Inc.
    Inventors: Theodora Salcedo, Steven M. Ruben, Craig A. Rosen, Vivian R. Albert, Claire Dobson, Tristan Vaughan
  • Chemokine ?-5
    Patent number: 7060261
    Abstract: The present invention relates to a novel CK?-5 protein which is a member of the alpha chemokine family. In particular, isolated nucleic acid molecules are provided encoding the human CK?-5 protein. CK?-5 polypeptides are also provided as are vectors, host cells and recombinant methods for producing the same. The invention further relates to screening methods for identifying agonists and antagonists of CK?-5 activity. Also provided are diagnostic methods for detecting immune system-related disorders and therapeutic methods for treating immune system-related disorders.
    Type: Grant
    Filed: April 3, 2002
    Date of Patent: June 13, 2006
    Assignee: Human Genome Sciences, Inc.
    Inventors: Ying-Fei Wei, Yi Li, Jian Ni, Craig A. Rosen, Steven M. Ruben
  • Secreted protein HRGDF73
    Patent number: 7053190
    Abstract: The present invention relates to novel human secreted proteins and isolated nucleic acids containing the coding regions of the genes encoding such proteins. Also provided are vectors, host cells, antibodies, and recombinant methods for producing human secreted proteins. The invention further relates to diagnostic and therapeutic methods useful for diagnosing and treating disorders related to these novel human secreted proteins.
    Type: Grant
    Filed: October 19, 2001
    Date of Patent: May 30, 2006
    Assignee: Human Genome Sciences, Inc.
    Inventors: Steven M. Ruben, Craig A. Rosen, Carrie L. Fischer, Daniel R. Soppet, Kenneth C. Carter, Daniel P. Bednarik, Gregory A. Endress, Guo-Liang Yu, Jian Ni, Ping Feng, Paul E. Young, John M. Greene, Ann M. Ferrie, Roxanne Duan, Jing-Shan Hu, Kimberly A. Florence, Henrik S. Olsen, Reinhard Ebner, Laurie A. Brewer, Yanggu Shi
  • Heregulin-like factor antibodies
    Patent number: 7049409
    Abstract: The present invention relates to a novel HLF protein which is a member of the heregulin family. In particular, isolated nucleic acid molecules are provided encoding the human HLF protein. HLF polypeptides are also provided as are vectors, host cells and recombinant methods for producing the same. The invention further relates to screening methods for identifying agonists and antagonists of HLF activity. Also provided are diagnostic methods for detecting disorders of the regulation of cell growth and therapeutic methods for treating disorders of the regulation of cell growth.
    Type: Grant
    Filed: July 1, 2003
    Date of Patent: May 23, 2006
    Assignees: Human Genome Sciences, Inc., Georgetown University Medical Center
    Inventors: Paul E. Young, C. Richter King, Mia Hijazi, Steven M. Ruben
  • Tumor necrosis factor receptor-5
    Patent number: 7049402
    Abstract: The present invention relates to a novel human gene encoding a polypeptide which is a member of the TNF receptor family, and has now been found to bind TRAIL. More specifically, an isolated nucleic acid molecule is provided encoding a human polypeptide named tumor necrosis factor receptor-5, sometimes referred to as “TNFR-5” or “TR5,” and now referred to hereinafter as “TRAIL receptor without intracellular domain” or “TRID.” TRID polypeptides are also provided, as are vectors, host cells, and recombinant methods for producing the same. The invention further relates to screening methods for identifying agonists or antagonists of TRAIL polypeptide activity. Also provided are diagnostic and therapeutic methods utilizing such compositions.
    Type: Grant
    Filed: April 5, 2001
    Date of Patent: May 23, 2006
    Assignee: Human Genome Sciences, Inc.
    Inventors: Ying-Fei Wei, Reiner Gentz, Jian Ni, Steven M Ruben
  • Use of vascular endothelial growth factor to treat photoreceptor cells
    Patent number: 7045496
    Abstract: The present invention is directed to VEGF-2 polynucleotides and polypeptides and methods of using such polynucleotides and polypeptides. In particular, provided are methods of treating retinal disorders with VEGF-2 polynucleotides and polypeptides.
    Type: Grant
    Filed: February 7, 2000
    Date of Patent: May 16, 2006
    Assignee: Human Genome Sciences, Inc.
    Inventors: Ralph Alderson, Robert Melder, Viktor Roschke, Steven M. Ruben, Craig A. Rosen
  • Peptidoglycan recognition proteins
    Patent number: 7041802
    Abstract: The present invention relates to three novel peptidoglycan recognition binding proteins expressed by keratinocytes, wound-healing tissues and chondrosarcoma tissue. More specifically, isolated nucleic acid molecules are provided encoding human peptidoglycan recognition protein-related proteins, referred to herein as PGRP-K (Keratinocytes), PGRP-W (Wound-healing), and PGRP-C (Chondrosarcoma) of FIGS. 1A–B, FIGS. 2A–C, and FIG. 3, respectively, each having homology to both human peptidoglycan recognition protein (PGRP) as well as murine Tag-7. PGRP-K, PGRP-W, and PGRP-C polypeptides are also provided. Further provided are vectors, host cells and recombinant methods for producing the same. The invention also relates to both the inhibition and enhancement of activities of PGRP-K, PGRP-W, and PGRP-c polypeptides and diagnostic methods for detecting PGRP-K, PGRP-W, and PGRP-C gene expression.
    Type: Grant
    Filed: June 27, 2002
    Date of Patent: May 9, 2006
    Assignee: Human Genome Sciences, Inc.
    Inventors: Paul E. Young, Steven M. Ruben, Craig A. Rosen, Henrik S. Olsen
  • Antibodies to monocyte-colony inhibitory factor (M-CIF)
    Patent number: 7041460
    Abstract: There are disclosed therapeutic compositions and methods using isolated nucleic acid molecules encoding a human myeloid progenitor inhibitory factor-1 (MPIF-1) polypeptide (previously termed MIP-3 and chemokine ?8 (CK?8 or ckb-8)); a human monocyte-colony inhibitory factor (M-CIF) polypeptide (previously termed MIP1-? and chemokine ?1 (CK?1 or ckb-1)), and a macrophage inhibitory protein-4 (MIP-4), as well as MPIF-1, M-CIF and/or MIP-4 polypeptides themselves, as are vectors, host cells and recombinant methods for producing the same.
    Type: Grant
    Filed: July 25, 2003
    Date of Patent: May 9, 2006
    Assignee: Human Genome Sciences, Inc.
    Inventors: Reiner L. Gentz, Brent L. Kreider, Jun Zhang, Michael Antonaccio, Donna Mendrick, Pablo Jimenez, Vikram Patel, Craig A. Rosen, Mark D. Adams, Haodong Li, Steven M. Ruben
  • Serum paraoxonase
    Patent number: 7026140
    Abstract: Human serum paraoxonase enzyme and DNA (RNA) encoding such serum paraoxonase enzymes are disclosed. Also provided is the procedure for producing such polypeptides by recombinant techniques. Uses of such polypeptides include their use as an antidote for organophosphate poisoning and to prevent neuronal cell death.
    Type: Grant
    Filed: September 2, 2004
    Date of Patent: April 11, 2006
    Assignee: Human Genome Sciences, Inc.
    Inventors: Peter L. Hudson, Wei Wu He, Steven M. Ruben
  • 53 human secreted proteins
    Patent number: 7026447
    Abstract: The present invention relates to novel human secreted proteins and isolated nucleic acids containing the coding regions of the genes encoding such proteins. Also provided are vectors, host cells, antibodies, and recombinant methods for producing human secreted proteins. The invention further relates to diagnostic and therapeutic methods useful for diagnosing and treating diseases, disorders, and/or conditions related to these novel human secreted proteins.
    Type: Grant
    Filed: October 30, 2001
    Date of Patent: April 11, 2006
    Assignee: Human Genome Sciences, Inc.
    Inventors: Craig A. Rosen, Steven M. Ruben, Charles Florence
  • Dendritic enriched secreted lymphocyte activation molecule
    Patent number: 7012134
    Abstract: The present invention relates to a novel human protein called Dendritic Enriched Secreted Lymphocyte Activation Molecule, and isolated polynucleotides encoding this protein. Also provided are vectors, host cells, antibodies, and recombinant methods for producing this human protein. The invention further relates to diagnostic and therapeutic methods useful for diagnosing and treating disorders related to this novel human protein.
    Type: Grant
    Filed: February 5, 2002
    Date of Patent: March 14, 2006
    Assignee: Human Genome Sciences, Inc.
    Inventors: Steven M. Ruben, Paul E. Young
  • Antibodies to secreted protein HEMCM42
    Patent number: 7001992
    Abstract: The present invention relates to novel human secreted proteins and isolated nucleic acids containing the coding regions of the genes encoding such proteins. Also provided are vectors, host cells, antibodies, and recombinant methods for producing human secreted proteins. The invention further relates to diagnostic and therapeutic methods useful for diagnosing and treating disorders related to these novel human secreted proteins.
    Type: Grant
    Filed: February 5, 2002
    Date of Patent: February 21, 2006
    Assignee: Human Genome Sciences, Inc.
    Inventors: Steven M. Ruben, Craig A. Rosen, Gregory A. Endress
  • Cytokine receptor common gamma chain like
    Patent number: 6982320
    Abstract: The present invention relates to a novel human protein called Cytokine Receptor Common Gamma Chain Like, and isolated polynucleotides encoding this protein. Also provided are vectors, host cells, antibodies, and recombinant methods for producing this human protein. The invention further relates to diagnostic and therapeutic methods useful for diagnosing and treating disorders related to this novel human protein.
    Type: Grant
    Filed: August 18, 1999
    Date of Patent: January 3, 2006
    Assignee: Human Genome Sciences, Inc.
    Inventors: Paul A. Moore, Craig A. Rosen, Steven M. Ruben
  • Chemokine ?-6
    Patent number: 6979443
    Abstract: The present invention relates to a novel CK?-6 protein which is a member of the alpha chemokine family. In particular, isolated nucleic acid molecules are provided encoding the human CK?-6 protein. CK?-6 polypeptides are also provided as are vectors, host cells and recombinant methods for producing the same. The invention further relates to screening methods for identifying agonists and antagonists of CK?-6 activity. Also provided are diagnostic methods for detecting CNS and immune system-related disorders and therapeutic methods for treating CNS and immune system-related disorders.
    Type: Grant
    Filed: March 4, 2002
    Date of Patent: December 27, 2005
    Assignee: Human Genome Sciences, Inc.
    Inventors: Ying-Fei Wei, Steven M. Ruben, Craig A. Rosen
  • Methods of using an agonistic antibody human tumor necrosis factor receptor (TR17)
    Patent number: 6969519
    Abstract: The present invention relates to a novel protein, TR17, which is a member of the tumor necrosis factor (TNF) receptor superfamily. In particular, isolated nucleic acid molecules are provided encoding the human TR17. TR17 polypeptides are also provided as anti TR17 antibodies and vectors, host cells and recombinant methods for producing the same. The invention further relates to methods of killing cells using the antibodies of the invention.
    Type: Grant
    Filed: September 25, 2001
    Date of Patent: November 29, 2005
    Assignee: Human Genome Sciences, Inc.
    Inventors: Steven M. Ruben, Kevin P. Baker